Klebsiella Pneumoniae Infections - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 47 pages report, published by Global Markets Direct

Keywords : Klebsiella Pneumoniae Infections Therapeutic Products under Development, Key Players in Klebsiella Pneumoniae Infections Therapeutics, Klebsiella Pneumoniae Infections Pipeline Overview, Klebsiella Pneumoniae Infections Pipeline, Klebsiella Pneumoniae Infections Pipeline Assessment

Report ThumbnailSeptember-2013
Klebsiella Pneumoniae Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Klebsiella Pneumoniae Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections. Klebsiella Pneumoniae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Klebsiella Pneumoniae Infections.
- A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Klebsiella Pneumoniae Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Klebsiella Pneumoniae Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Klebsiella Pneumoniae Infections, H2 2013 7
  • Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Discovery and Pre-Clinical Stage Products, H2 2013 11
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Klebsiella Pneumoniae Infections, H2 2013 7
  • Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 10
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11
  • Products under Development by Companies, H2 2013 12
  • Dainippon Sumitomo Pharma Co., Ltd., H2 2013 13
  • Rib-X Pharmaceuticals, Inc., H2 2013 14
  • Cubist Pharmaceuticals, Inc., H2 2013 15
  • Pfizer Inc., H2 2013 16
  • Phico Therapeutics Ltd., H2 2013 17
  • Trana Discovery, Inc., H2 2013 18
  • Cantab Biopharmaceuticals Limited, H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Klebsiella Pneumoniae Infections Therapeutics - Drug Profile Updates 36
  • Klebsiella Pneumoniae Infections Therapeutics - Discontinued Products 38
  • Klebsiella Pneumoniae Infections Therapeutics - Dormant Products 39
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Klebsiella Pneumoniae Infections Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Klebsiella Pneumoniae Infections 7
  • Klebsiella Pneumoniae Infections Therapeutics under Development by Companies 9
  • Discovery and Pre-Clinical Stage Products 11
  • Comparative Analysis 11
  • Klebsiella Pneumoniae Infections Therapeutics - Products under Development by Companies 12
  • Companies Involved in Klebsiella Pneumoniae Infections Therapeutics Development 13
  • Dainippon Sumitomo Pharma Co., Ltd. 13
  • Rib-X Pharmaceuticals, Inc. 14
  • Cubist Pharmaceuticals, Inc. 15
  • Pfizer Inc. 16
  • Phico Therapeutics Ltd. 17
  • Trana Discovery, Inc. 18
  • Cantab Biopharmaceuticals Limited 19
  • Klebsiella Pneumoniae Infections - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • RX-04 - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • SASPject PT-3.X - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • Gram-Negative Programme - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • Snare Antibacterial For Gram Negative Infections - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • CB-027 - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • MVX-506 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • SM-295291 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • SM-369926 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Dap-3 Polymyxin Analogs - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • Antimicrobial Compounds Program - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • Klebsiella Pneumoniae Infections Therapeutics - Drug Profile Updates 36
  • Klebsiella Pneumoniae Infections Therapeutics - Discontinued Products 38
  • Klebsiella Pneumoniae Infections Therapeutics - Dormant Products 39
  • Klebsiella Pneumoniae Infections - Product Development Milestones 40
  • Featured News & Press Releases 40
  • Apr 29, 2013: Basilea Pharma To Present Data On Sulfactam Antibiotic BAL30072 At ECCMID 2013 40
  • Sep 12, 2012: Merck Announces Presentation Of Scientific Data On Investigational Agent MK-7655 At 52nd Annual ICAAC 40
  • Sep 12, 2012: Rib-X Pharma Presents Preclinical Studies With New Classes Of RX-04 Antibiotic Compounds At ICAAC 42
  • Sep 12, 2012: Phico Therapeutics Achieves Developmental Milestone In Fight Against Multidrug Resistant Bacteria Enzyme NDM-1 43
  • Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 45
  • Sep 05, 2012: Rib-X Pharma To Present Data On RX-04 Program At ICAAC 2012 45
  • Appendix 46
  • Methodology 46
  • Coverage 46
  • Secondary Research 46
  • Primary Research 46
  • Expert Panel Validation 46
  • Contact Us 47
  • Disclaimer 47

Please select a license type

Share

Related Products

Global Markets DirectKlebsiella Pneumoniae Infections - Pipeline Review, H2 2013Product ThumbnailKlebsiella Pneumoniae Infections - Pipeline Review, H2 2013, Industry ReportProduct #: 113313
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved